SOURCE: Masimo

Masimo

October 13, 2014 20:01 ET

Newborn Foundation Bestows Masimo CEO Joe Kiani With the Hubert H. Humphrey 'Dawn of Life' Award

Awards Gala Marked Largest Fundraiser of Its Kind to Raise Awareness to Combat Newborn Mortality

IRVINE, CA--(Marketwired - Oct 13, 2014) - The Newborn Foundation presented Joe Kiani, founder, CEO and Chairman of the Board of Masimo (NASDAQ: MASI), with the Hubert H. Humphrey "Dawn of Life" Award at its gala Friday night in Minneapolis, Minn., an honor previously reserved for members of Congress.

Billed as the largest fundraiser of its kind to raise awareness for combatting newborn mortality, all proceeds from the awards gala will go to the continued efforts of the Newborn Foundation | Coalition to leverage technologies that improve early detection of health conditions and access to care for newborns.

Hubert "Buck" Humphrey IV, the former Vice President's grandson, presented the Dawn of Life award to Kiani as a "visionary leader who has been dedicated to increasing the role of technology and innovation in improving health" of newborns around the world.

Kiani received the "Dawn of Life" Award the same day Masimo announced CE Mark of Eve™ Newborn Screening Software Application* for Radical-7® Pulse CO-Oximeters, designed to help clinicians more effectively and efficiently screen newborns for critical congenital heart disease (CCHD).

"Joe's work has been truly outstanding," said Annamarie Saarinen, co-founder and CEO of the Newborn Foundation. "It's been a privilege to have his wisdom and support in pursuit of improving newborn health and patient safety."

"My friend Joe Kiani is deeply committed to patient safety and reducing preventable death," said former U.S. Surgeon General Dr. Richard Carmona, M.D. "When I heard Joe was receiving the Hubert H. Humphrey 'Dawn of Life' Award, I was deeply moved. The former vice president was one of the staunchest advocates for the health of those most in need -- the youngest, most fragile among us."

The Newborn Foundation was launched after Saarinen's daughter, Eve, was diagnosed and treated for critical congenital heart defects as a newborn. She was only able to survive because of early detection and access to life-saving intervention. In just a few short years, the Newborn Foundation's advocacy and policy leadership have impacted the landscape of newborn health - and helped save lives. Today, nearly all 4 million babies born each year in the U.S. are being screened with pulse oximetry for heart defects and other serious health conditions and the Newborn Foundation's projects are impacting the hardest to reach and most underserved babies across the nation.

The Foundation's work has also expanded internationally, with vital screening, telehealth and infrastructure programs in Morocco, the Philippines and rural China. A partner of the United Nations' Every Newborn Action Plan - Masimo and the Newborn Foundation's BORN Project were highlighted at a global meeting of delegates in Johannesburg this year as being among a handful of programs that are saving newborn lives.

Stated Kiani: "I am truly humbled and honored to receive the Newborn Foundation's 'Dawn of Life' Award. The Newborn Foundation is a tireless advocate for those who can't yet speak for themselves -- babies born with heart and other conditions, who can be saved with early detection and intervention. I, and all of us at Masimo, look forward to continue working alongside the Newborn Foundation, with the goal of eliminating preventable deaths of newborns."

Eve™ is not available in the United States.

* Referred to as "CCHD Mode" in Radical-7

About the Newborn Foundation
The Newborn Foundation is an international non-profit working specifically to leverage health IT and medical technologies to improve access and outcomes while reducing disparities for newborns. The organization has been integral in the policy development, adoption and implementation of technologies for early detection, intervention and care of the youngest patients, including the landmark addition of universal newborn screening with pulse oximetry as a public health initiative. The work has now moved international, with vital newborn health projects in the UK, Morocco, the Philippines and rural China. Visit www.newbornfoundation.org

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: whether Mr. Kiani's receipt of the Dawn of Life award will have any material effect on our business, as well as other factors discussed in the Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation.

Contact Information